share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP:信函
美股SEC公告 ·  08/23 13:08

Moomoo AI 已提取核心訊息

SeaStar Medical Holding Corporation has officially requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, as per a letter dated August 23, 2024. The company, headquartered in Denver, Colorado, seeks to have the Registration Statement become effective at 4:30 p.m. Eastern Time on August 27, 2024, or as soon as possible thereafter. SeaStar Medical's CEO, Eric Schlorff, signed the request, which was submitted via EDGAR, the SEC's electronic filing system. The company has also arranged for its counsel, Dorsey & Whitney LLP, to receive oral confirmation of the Registration Statement's effectiveness once declared.
SeaStar Medical Holding Corporation has officially requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, as per a letter dated August 23, 2024. The company, headquartered in Denver, Colorado, seeks to have the Registration Statement become effective at 4:30 p.m. Eastern Time on August 27, 2024, or as soon as possible thereafter. SeaStar Medical's CEO, Eric Schlorff, signed the request, which was submitted via EDGAR, the SEC's electronic filing system. The company has also arranged for its counsel, Dorsey & Whitney LLP, to receive oral confirmation of the Registration Statement's effectiveness once declared.
SeaStar Medical控股公司正式請求美國證券交易委員會(SEC)加速其S-3表格的註冊聲明生效日期,日期爲2024年8月23日的一封信中。總部位於科羅拉多州丹佛市的該公司希望註冊聲明可在2024年8月27日東部時間下午4:30生效,或儘快生效。SeaStar Medical的首席執行官埃裏克·施洛夫(Eric Schlorff)簽署了該請求,該請求是通過EDGAR系統(SEC的電子申報系統)提交的。該公司還安排其律師事務所Dorsey & Whitney LLP在註冊聲明一經宣佈生效後接到口頭確認。
SeaStar Medical控股公司正式請求美國證券交易委員會(SEC)加速其S-3表格的註冊聲明生效日期,日期爲2024年8月23日的一封信中。總部位於科羅拉多州丹佛市的該公司希望註冊聲明可在2024年8月27日東部時間下午4:30生效,或儘快生效。SeaStar Medical的首席執行官埃裏克·施洛夫(Eric Schlorff)簽署了該請求,該請求是通過EDGAR系統(SEC的電子申報系統)提交的。該公司還安排其律師事務所Dorsey & Whitney LLP在註冊聲明一經宣佈生效後接到口頭確認。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息